Navigation Links
Xanodyne Expands U.S. Sales Force and Launches Zipsor(TM) (diclofenac potassium) Liquid Filled Capsules
Date:11/12/2009

NEWPORT, Ky., Nov. 12 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that the U.S. launch of Zipsor(TM) (diclofenac potassium) Liquid Filled Capsules, is now underway and being supported by an expanded 250-member specialty sales force.

In June 2009, Xanodyne received Food and Drug Administration (FDA) approval for Zipsor, a new treatment option for relief of mild to moderate acute pain in adults (18 years of age or older). With the national launch of Zipsor, Xanodyne has now successfully executed on two key elements of its business model - R&D and commercialization.

Commenting on the launch, Natasha Giordano, Chief Commercial Officer, said, "The launch of Zipsor was a tremendous achievement for Xanodyne. Within 90 days of receiving FDA approval, we were able to scale up our commercial organization and secure broad distribution at retail pharmacies for the product."

Giordano added, "This is an exciting time for Xanodyne as we seek to gain a foothold in the pain marketplace with Zipsor. Our newly expanded team of experienced sales representatives enables Xanodyne to achieve a greater geographic reach and frequency of product details to healthcare professionals across the United States."

Xanodyne remains committed to aggressively executing its product commercialization strategy for its emerging product portfolio. The Company expects FDA action soon on Lysteda(TM) (formerly XP12B), an oral tranexamic acid compound under priority review for the potential treatment of women suffering from heavy menstrual bleeding.

About Xanodyne

Xanodyne Pharmaceuticals, Inc., which commenced operations in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's heal
'/>"/>

SOURCE Xanodyne Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Xanodyne Raises $50 Million in Equity Financing to Support Emerging Product Portfolio
2. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
3. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
4. Cellectar Expands Clinical Management Team
5. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
6. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
7. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
8. PAREXEL Expands Global Clinical Pharmacology Capabilities
9. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
10. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
11. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... N.J. , Sept. 17, 2014  Bayer HealthCare ... National Hemophilia Foundation,s 66 th Annual Meeting, which ... , D.C.  The data, which will be shared through ... treatment and patient care. Data will be presented in ... research into treatment modalities in hemophilia A patients, Bayer ...
(Date:9/17/2014)... , September 17, 2014 According ... by Component (Sensor, Battery, Memory Device, Display, & Microprocessor/MCU), ... & Wellness), and by Geography - Global Forecast to ... electronics market is expected to reach $56.50 Billion by ... to 2020. Browse 235 market data Tables ...
(Date:9/17/2014)... CITY, Utah , Sept. 17, 2014 /PRNewswire/ ... an exclusive global licensing and collaboration agreement with ... and commercialize NuView,s investigative genomic-based diagnostic biomarker to ... agreement also includes all other future diagnostic-imaging applications. ... for in-vivo therapeutic delivery and in-vitro urine screen ...
Breaking Medicine Technology:Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5
... WORCESTER, Mass. and TORONTO, May 17, 2012  Generex ... today that new members have joined the Scientific ... Express, Inc. for the company,s AE37 breast cancer ... N. Hortobagyi, MD, FACP (University of Texas MD ...
... TUCSON, Ariz., May 17, 2012 SynCardia Systems, Inc. ... only FDA, Health Canada and CE (Europe) approved Total ... March 31, 2012, due in part to Certified Centers ... SynCardia temporary Total Artificial Heart . ...
Cached Medicine Technology:Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine 2Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine 3Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine 4SynCardia Posts Record Revenue and Profit in Q1 2012 2SynCardia Posts Record Revenue and Profit in Q1 2012 3
(Date:9/17/2014)... WEDNESDAY, Sept. 17, 2014 (HealthDay News) -- Present-day ... groups of ancient humans, according to a new ... descended from indigenous hunter-gatherers and early European farmers. ... samples revealed they are also the descendants of ... genetic material from this third ancestral group, researchers ...
(Date:9/17/2014)... Dennis Thompson HealthDay Reporter ... Diabetics and dieters who turn to artificial sweeteners to ... any favors, a new Israeli study suggests. Artificial ... containing no calories, researchers found in human and mouse ... to alter the bacteria residing in the intestines in ...
(Date:9/17/2014)... Research has shown that most 18-month-olds learn an ... however, little is known about how children process information ... preschool years. In a new study, a University of ... as they age, and a limit exists as to ... findings could help parents enhance their children,s vocabularies and ...
(Date:9/17/2014)... In a country where 77% of ... regular basis, how can Americans find healthy and fulfilling ... Stress Challenge , a 5-day interactive journey to putting ... From September 29th – October 3rd, the Hyland’s ... to specific topics that promote natural solutions for managing ...
(Date:9/17/2014)... Doheny HealthDay Reporter WEDNESDAY, ... beverage companies have made good on their pledge to cut ... The companies, acting together through the Healthy Weight Commitment Foundation, ... 2007 and 2012 and 1.5 trillion by 2015. They,ve actually ... collectively met their pledge and exceeded their pledge," said lead ...
Breaking Medicine News(10 mins):Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 3Health News:Artificial Sweeteners May Raise Blood Sugar Levels: Study 2Health News:Artificial Sweeteners May Raise Blood Sugar Levels: Study 3Health News:Babies learn words differently as they age, researcher finds 2Health News:Stress Less with the Hyland's 5-Day Stress Challenge 2Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 2Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 3
... in patients aged 80 and older, researchers say , ... questions the widespread use of implantable cardiac devices in ... in the hospital after receiving the devices. , Patients ... implantable defibrillators and pacemakers, even though most clinical trials ...
... no longer safe on the road , MONDAY, April ... input from family members are the most useful tools in ... or other dementia sets in, according to new guidelines from ... assessments are usually more accurate than the patient,s own opinion ...
... expert says , MONDAY, April 12 (HealthDay News) -- A ... in the blood raises the risk of heart disease for ... however, is not seen in men, according to the report, ... . , The study, by researchers at Italy,s National Cancer ...
... Important advances in the fight against cancer have come as ... were previously unknown to scientists. A new study led ... activate a viral infection that, paradoxically, can help anti-viral medications ... a team of UNC School of Medicine scientists and the ...
... In an ongoing effort to scientifically validate the age-old belief ... of patients, The University of Texas M. D. Anderson Cancer ... the efficacy of incorporating yoga into the treatment program of ... ever awarded by the National Cancer Institute for the study ...
... pain can go on too long and be ineffective, study ... that many patients with terminal cancer don,t benefit from getting ... symptoms like pain. , The researchers, who reported their findings ... Cancer , say doctors are failing to properly adjust treatments ...
Cached Medicine News:Health News:Study Questions Use of Heart Device Implants in the Very Old 2Health News:Docs Issue Guidelines for Drivers With Dementia 2Health News:Docs Issue Guidelines for Drivers With Dementia 3Health News:Simple Carbs Pose Heart Risk for Women 2Health News:Simple Carbs Pose Heart Risk for Women 3Health News:UNC study offers first clinical evidence of anti-cancer drug triggering viral infection 2Health News:M. D. Anderson receives 4.5 million grant, largest ever for study of yoga and cancer 2Health News:Many Terminal Cancer Patients May Be Overtreated 2
High sensitive, specific one step immunochromatographic assay for human infectious disease...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
Detection of Malarial antigen in Human whole blood....
The KAT-Quick Malaria test was designed for the diagnosis of Malaria, in laboratories, the home and for medical kits when travelling into malaria regions....
Medicine Products: